App-Quantinova.ai

Palliative care intervention and aggressive care at end-of-life in patients with advanced pancreatic adenocarcinoma.

Caitlin Lees - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.

Ashwathy Susan Mathew - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients.

Nivethan Vela - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Provider-volume associated with variable receipt of therapy and outcomes for noncurative pancreas adenocarcinoma: A population-based analysis.

Julie I. Hallet - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.

Sharlene Gill - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application.

Jared Adams - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lanreotide

Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.

Lucy Xiaolu Ma - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Bryan Anthony Chan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Efficacy and tolerability of sorafenib in unresectable/advanced hepatocellular carcinoma patients: Real-life experience in a Hong Kong tertiary liver cancer institute.

Thomas Cheung Yau - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Symptom burden of patients with advanced pancreas cancer (APC): A provincial cancer institute observational study.

Julie Ward - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.

Jorge Chaves Porras - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

N/A

Treatment sequencing in MPC, insights from a 3˚ care center.

Ivan Barrera - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Outcomes of stereotactic body radiotherapy for unresectable hepatocellular carcinoma.

Yizhou Zhao - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis.

Christina Kim - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

N/A

Tumor platinum concentrations and pathological responses following preoperative cisplatin-containing chemotherapy in gastric or gastroesophageal junction cancer patients.

Yanshuo Cao - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cisplatin

Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).

Andrea S. Fung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion.

Pablo Munoz-Schuffenegger - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

A study of pelareorep in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).

Devalingam Mahalingam - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.

Andrea S. Fung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Undertreatment of noncurative pancreatic adenocarcinoma? A population-based analysis of patterns of care.

Michail Mavros - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Filters

28841 Abstracts